Hospital

Expert explains how delaying BCOP certification too long after a PGY2 residency can cause a “if you don’t use it, you’ll lose it” problem.

Certain states are proposing that out-of-state telemedicine care should be more accessible, which researchers believe is a trend that will continue.

A new cell isolation kit was approved by the FDA to decrease the amount of time needed in a lab and lower overall costs for testing tuberculosis.

The annual report notes that progress in reducing cancer mortality is uneven among populations, with minority groups not seeing the same benefits from therapeutic advances.

Motivational Interviewing is a collaborative conversation style that can empower patients to stay the course and achieve better outcomes.

Specialty pharmacies need processes, systems and tools to quickly determine medication delivery status, reassure confidence, and alleviate patient anxiety.

Innovative system reveals a pair of potential therapies for autosomal recessive polycystic kidney disease, which currently has no FDA-approved treatments.

The study also showed sustained reductions in hospitalizations over a 2-year period of FreeStyle Libre system use.

Outpatient treatment is primarily based on patient-specific factors, whereas oseltamivir remains the therapy of choice for inpatient settings.

Research suggests that acupuncture may be able to clinically reduce symptoms of anxiety in this patient population.

Program will start to distribute a free HIV self-test to people who enroll by early 2023.

Danielle Carnival, PhD, addressed the National Comprehensive Cancer Network Policy Summit on Friday.

Semaglutide is a traditional type 2 diabetes treatment that may help obese individuals lose weight, especially if given at a higher dose.

The FDA accepted a supplemental New Drug Application for tucatinib to treat HER2 colorectal cancer, which could significantly improve outcomes for these patients.

The All of Us Research Program looks to enroll more than 1 million US individuals in the next 10 years to enable public access to medical data for research purposes.

Selpercatinib produced clinically meaningful and durable responses across a variety of tumor types in patients with RET-driven cancers.

After 4 years, the 1-time cost of valoctocogene roxaparvovec appeared to be more cost-effective than the annual cost of emicizumab prophylaxis for hemophilia A, according to a new Draft Evidence Report.

Data showed that Black women, regardless of education level or income, are more likely to reside in disadvantaged neighborhoods, which may contribute to racial disparities in breast cancer.

Eliminating paper prescriptions allows for greater legibility, security, trackability for pharmacists, providers.

Nivolumab is a biomarker that has been shown to benefit the survival of patients with stage 2 melanoma patients compared with placebo.

Pharmacists are an essential part of improving care for patients with epilepsy.

This study highlights one benefit of the integrated health system specialty pharmacy model for patients who are prescribed acalabrutinib.

Second- and third-generation individuals living in Los Angeles, California, demonstrate 35% and 61%, respectively, more of a chance of getting the disease, according to new study results.

Revised program will analyze the once-daily oral combination of doravirine 100 mg and a lower dose of islatravir in adults with HIV-1 infection.

Black women are suggested to be diagnosed with stage 3 HR-positive breast cancer and receive longer neoadjuvant endocrine therapy more often than White women.

Phase 3 TOPAZ-1 trial of AstraZeneca’s durvalumab demonstrates an improved overall survival benefit.

AstraZeneca’s Lynparza in combination or as a monotherapy demonstrates meaningful survival benefit in long-term follow-up.

Amendments reflecting more contemporary options could raise ethical questions for health care workers.